Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you have PCOS and you're struggling with weight, you're not fighting a willpower problem — you're fighting a hormonal one. Weight loss injections such as tirzepatide (Mounjaro) and semaglutide (Wegovy) target the appetite and blood-sugar pathways that PCOS disrupts, and early evidence suggests many people with the condition respond well. These are prescription-only medicines, which means a prescriber must assess whether they are suitable for you personally before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people with PCOS hear the same advice from an early age: lose weight and the symptoms will improve. What that advice tends to skip over is the reason weight is harder to shift in the first place. Insulin resistance, a core feature of PCOS in the majority of cases, raises circulating insulin, promotes fat storage particularly around the abdomen, and blunts the body's normal hunger signals. The result is that standard calorie-counting approaches often produce far less weight loss than they would in someone without the condition.
GLP-1 receptor agonists like semaglutide (Wegovy) work by slowing how quickly food leaves the stomach, suppressing appetite through gut-hormone pathways, and improving insulin sensitivity, exactly the mechanisms that PCOS tends to compromise. Tirzepatide (Mounjaro) adds a second pathway, activating GIP receptors as well, making it the only dual-agonist weight medicine licensed in the UK. You can read more about how these options compare on our weight loss injections overview.
Neither medicine is licensed specifically for PCOS. Their UK licences cover weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition, and insulin resistance or related metabolic features of PCOS can fall into that category. A prescriber assessing your specific situation will look at your full history, not just the number on the scale. The NHS patient guide to tirzepatide covers the licensed uses and key safety points clearly.
There is a meaningful body of evidence showing that GLP-1 medicines improve insulin sensitivity and assist weight loss in women with PCOS, and several smaller trials have reported improvements in menstrual regularity and androgen levels alongside the weight changes. That is encouraging, and it is why many endocrinologists and gynaecologists have begun discussing these treatments with their PCOS patients.
At the same time, the largest phase-3 trials (SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide, published in the New England Journal of Medicine) enrolled broad adult populations rather than PCOS-specific cohorts. So while the headline average weight losses of roughly 20% and 15% respectively give a useful benchmark, they cannot simply be assumed to apply identically to everyone with PCOS. Responses vary, and a prescriber will set realistic expectations with you rather than quoting a single figure as a promise.
Our page on whether weight loss injections can help with PCOS goes deeper on the specific evidence. What is settled is that these are not quick fixes or cosmetic tools, the MHRA and DHSC are explicit on this point. They are medicines for managing a chronic condition, used alongside changes to diet and activity.
Many people with PCOS experience irregular cycles or are told they may have difficulty conceiving. That makes the contraception conversation around these medicines particularly important, and sometimes surprising.
Tirzepatide and semaglutide are not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. Treatment should be stopped before attempting pregnancy, and the prescriber will advise on timing. With tirzepatide specifically, because the medicine slows gastric emptying, the absorption of oral contraceptive pills can be reduced. NHS guidance recommends adding a non-oral method (such as condoms) for the first four weeks of treatment and for four weeks after each dose increase. You can find the detail on this in NHS England's guidance on weight management injections.
There is also a practical point that sometimes catches people off guard: some women with PCOS who believed they were unlikely to conceive have become pregnant after losing weight on these medicines, as menstrual cycles regulate. Reliable contraception is therefore not an optional extra, it is a clinical requirement throughout treatment if there is any possibility of pregnancy. If you are planning a family in the near future, this is one of the most important conversations to have with your prescriber before starting. If you want to understand more about how a weight loss injection works as a treatment before that conversation, our dedicated page walks through the key details.
For a sense of how our clinical team approaches these situations, our prescribers' profile gives some context on what clinician-led review means in practice.
If NHS access is not available to you (and for many people with PCOS the waiting lists and eligibility criteria mean it is not) a private prescription route through a GPhC-registered pharmacy is the lawful alternative. At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the day it is submitted. There is no algorithm ticking boxes. A real clinician looks at your answers, your weight, your history. Patients with certain neurological conditions sometimes ask us about interactions with their existing care, and our page covering MS and weight loss injections shows the kind of condition-specific detail we provide across different health contexts.
Identity and weight are verified before treatment is confirmed. Once a prescriber approves, the pen is dispatched the same day for orders placed before 12pm Monday to Friday, and arrives by DPD the next working day in plain, unmarked packaging, the tracking notification comes to your phone, and the pen itself is ready to go in the fridge door. If you have questions after it arrives, our aftercare team is available seven days a week. Patients who ask about complementary approaches sometimes explore our guide to NAD injections and weight loss, which sets out where that option fits alongside other treatments.
Explore whether this could be the right route for you on our weight loss treatments page, or take a look at our treatment overview if you want to compare the options first. If you are curious about specific PCOS considerations when choosing a medicine, our guide to the best weight loss injection for PCOS may help you form the right questions before your consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.